Article
677C > T and 1298A > C MTHFR polymorphisms affect arechin treatment outcome in rheumatoid arthritis.
Pharmacological reports : PR - 1 Jan 2000
Pawlik Andrzej, Kurzawski Mateusz, Górnik Wanda, Dabrowska-Zamojcin Ewa, Droździk Marek
Abstract excerpt
Despite the availability of several new agents for the treatment of rheumatoid arthritis (RA), arechin (hydroxychloroquine) remains the mainstay because of both cost-effectiveness and experience with its use. However, there is considerable variation in response to this drug, with toxicity limiting treatment in some patients. Methylenetetrahydrofolate reductase (MTHFR) is involved in the folate metabolism and has...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
